How low can you go? Use of low- and standard-dose liposomal amphotericin B for treatment of invasive fungal infections

• Published in: International journal of infectious diseases Vol. 17; no. 8; pp. e615 - e620
• Main Authors: Kassamali, Zahra, Danziger, Larry H., Glowacki, Robert C., Schwartz, David N.
• Format: Journal Article
• Language: English
• Published: Canada Elsevier Ltd 01.08.2013
• Subjects: Adult; adults; Aged; Aged, 80 and over; amphotericin B; Amphotericin B - administration & dosage; Amphotericin B - adverse effects; Antifungal Agents - administration & dosage; Antifungal Agents - adverse effects; Antifungal pharmacology; Candida; Female; Fungal infections; fungi; Hospitalization; Humans; hypokalemia; Infectious Disease; Liposomal amphotericin B; Liposomes; Male; Middle Aged; Mycoses - drug therapy; Mycoses - mortality; nephrotoxicity; pathogens; patients; Pulmonary/Respiratory; Retrospective Studies; statistics; Treatment Outcome; Young Adult; Antifungal pharmacology; Liposomal amphotericin B; Fungal infections
• ISSN: 1201-9712; 1878-3511; 1878-3511
• DOI: 10.1016/j.ijid.2013.01.015

Recommended doses of liposomal amphotericin B (L-AMB) range from 3 to 6mg/kg/day, but 1mg/kg/day may be equally effective and a lower cost alternative for many indications. The objective of this analysis was to assess indications and clinical outcomes of patients who received low-dose (1mg/kg/day ro...